Osamu Aramaki

Osamu Aramaki

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in BioScience Trends
Verified
Journal Article
Open access
PDF file
THTokio Higaki
Tokio Higaki
OAOsamu Aramaki
Osamu Aramaki
MMMasamichi Moriguchi
Masamichi Moriguchi
HNHisashi Nakayama
Hisashi Nakayama
YMYutaka Midorikawa
Yutaka Midorikawa
TTTadatoshi Takayama
Tadatoshi Takayama
Conventional regimens for unresectable intrahepatic cholangiocarcinoma are considered of limited effectiveness. To evaluate the efficacy and toxicity of combination chemotherapy with hepatic arterial infusion of IA-call (a fine-powder formulation of cisplatin) plus oral S-1 in patients with unresectable intrahepatic cholangiocarcinoma. The clinicopathological data and long-term outcome of 12 patients who were received with IA-call plus S-1 were compared with those of 16 patients who were received other treatments, such as radiation therapy, trans-arterial chemoembolization, and systemic chemotherapy. The IA-call plus S-1 regimen consisted of IA-call (65 mg/m2, administered into the hepatic artery) on day 1 and oral S-1 (60 mg/m2/day) on days 1-28, every 42 days, repeated cycle. Prognostic factors of these patients were evaluated by uni- and multivariate analysis. There was no significant difference between the two groups in the disease status, such as the number of tumor and the tumor size. The overall survival was significantly longer in the patients receiving the arterial IA-call and S-1 regimen (median survival time = 10.1; range, 3.6-24.2 months) than in the receiving other treatments (median survival time = 4.0; range; 0.3-24.2 months, p = 0.01). The multivariate analysis revealed that chemotherapy regimen was significantly related to survival, with a hazard ratio of 3.97 (p = 0.02). In the IA-call plus S-1 group, the overall response rate was 33.3%. The major toxic effect was grade 3 anemia, occurring in 1 patient (4.5%). Combination chemotherapy with arterial IA-call plus oral S-1 is an effective regimen that may improve survival in patients with unresectable intrahepatic cholangiocarcinoma.

31 October 2020 in BioScience Trends
Verified
Journal Article
Open access
PDF file
YMYutaka Midorikawa
Yutaka Midorikawa
TTTadatoshi Takayama
Tadatoshi Takayama
THTokio Higaki
Tokio Higaki
OAOsamu Aramaki
Osamu Aramaki
KTKenichi Teramoto
Kenichi Teramoto
MMMitsuhiko Moriyama
Mitsuhiko Moriyama
A low platelet count, one of parameters of portal hypertension, is clinically a predictor of postoperative mortality, while platelets induce tumor development during growth factor secretion. In this study, we retrospectively investigated whether high platelet count negatively affects the survival of patients with hepatocellular carcinoma (HCC). Patients undergoing initial and curative resection for HCC were included. Surgical outcomes were compared between the high platelet (platelet count ≥ 20 × 104/μL) and control (< 20 × 104/μL) groups in patients without cirrhosis and between the low platelet (< 10 × 104/μL) and control (≥ 10 × 104/μL) groups in patients with cirrhosis. Among patients without cirrhosis, tumor was larger (P < 0.001) and tumor thrombus was more frequent (P < 0.001) in the high-platelet group than in the control group. After a median follow-up period of 3.1 years (range 0.2-16.2), median overall survival was 6.3 years (95% confidence interval [CI], 5.3-7.8) and 7.6 years (6.6-10.9) in the high-platelet (n = 273) and control (n = 562) groups, respectively (P = 0.027). Among patients with cirrhosis, liver function was worse (P < 0.001) and varices were more frequent (P < 0.001) in the low-platelet group. The median overall survival of patients in the low-platelet group (n = 172) was significantly shorter than that of patients in the control group (n = 275) (4.5 years [95% CI, 3.7–6.0] vs. 5.9 years [4.5-7.5], P = 0.038). Taken together, thrombocytopenia indicates poor prognosis in HCC patients with cirrhosis, while thrombocytosis is a poor prognostic predictor for those without cirrhosis.

29 May 2020 in Surgery Today
Verified
Journal Article
Closed access
PDF file
NKNaoya Kobayashi
Naoya Kobayashi
OAOsamu Aramaki
Osamu Aramaki
YMYutaka Midorikawa
Yutaka Midorikawa
THTokio Higaki
Tokio Higaki
HNHisashi Nakayama
Hisashi Nakayama
TTTadatoshi Takayama
Tadatoshi Takayama

18 October 2022 in Hepatology Research
Verified
Journal Article
Closed access
OAOsamu Aramaki
Osamu Aramaki
TTTadatoshi Takayama
Tadatoshi Takayama
YMYutaka Matsuyama
Yutaka Matsuyama
SKShoji Kubo
Shoji Kubo
NKNorihiro Kokudo
Norihiro Kokudo
MMMasatoshi Makuuchi
Masatoshi Makuuchi

28 February 2021 in BioScience Trends
Verified
Journal Article
Closed access
PDF file
MHMasaharu Harada
Masaharu Harada
OAOsamu Aramaki
Osamu Aramaki
YMYutaka Midorikawa
Yutaka Midorikawa
THTokio Higaki
Tokio Higaki
HNHisashi Nakayama
Hisashi Nakayama
TTTadatoshi Takayama
Tadatoshi Takayama
There is little information on the impact of aging on liver resection of hepatocellular carcinoma (HCC). The aim of study was to evaluate the prognostic impact of the patient's age on the long-term survival after resection of HCC. The postoperative outcomes of the 291 elderly (≥ 70 years) and 340 younger (< 70 years) patients underwent curative liver resection for HCC were analyzed using multivariate and propensity-score matching. Risk score were calculated from the results of Cox regression analysis. The overall survival rate was significantly lower in the elderly group than that in the younger group (p = 0.01). Factors related to overall survival were vascular invasion (absent vs. present, HR 2.25; 95% CI 1.52-3.33, p = 0.0001), albumin level (< 3.0 vs. ≥ 3.0 g/dl, HR 2.23; 95% CI 1.31-3.79, p = 0.003), and number of tumors (solitary vs. multiple, HR 1.68; 95% CI 1.24-2.27, p = 0.001). The results of risk-score analysis with a Cox proportional-hazards model indicated that the proportion of poor-risk patients was significantly higher in the elderly than in the younger group. Propensity-score matching analysis yielded 234 pairs of patients. There were no significant differences in baseline profiles or risk scores between the two groups (p = 0.43). There were also no significant differences in the overall survival between the two groups (p = 0.23). Advanced age does not have a significant impact on the outcomes of patients after resection of HCC.

1 December 2015 in Surgery
Verified
Journal Article
Closed access
OAOsamu Aramaki
Osamu Aramaki
TTTadatoshi Takayama
Tadatoshi Takayama
THTokio Higaki
Tokio Higaki
HNHisashi Nakayama
Hisashi Nakayama
TOTakao Okubo
Takao Okubo
MMMasamichi Moriguchi
Masamichi Moriguchi